Filing Flows › Nuvation Bio (NUVB) › Q3 2026 › vs Q2 2026
Nuvation Bio (NUVB) Q3 2026 vs Q2 2026 (quarter over quarter)
Nuvation Bio's revenue rose $13.3M (+42%) from $31.7M in Q2 2026 to $45.0M in Q3 2026. The biggest changes: License +$9.0M (+106%); Product Revenue +$4.3M (+19%).
Nuvation Bio, Q3 2026: revenue $45.0M (+243% year over year), operating margin -93.9%, net loss $41.9M, operating cash flow −$38.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product Revenue | $27.5M | $23.2M | $4.3M | +19% |
| License | $17.5M | $8.5M | $9.0M | +106% |
| Revenue | $45.0M | $31.7M | $13.3M | +42% |
| Other income, net | $311K | −$11.8M | $12.1M | — |
| Net loss | $41.9M | $62.8M | −$20.9M | -33% |
| Costs & expenses | $87.2M | $94.5M | −$7.4M | -8% |
| Operating costs | $87.2M | $82.7M | $4.4M | +5% |
| Research & development | $32.7M | $30.7M | $2.0M | +7% |
| SG&A | $42.6M | $42.6M | −$38K | -0.1% |
| Other operating costs | $11.9M | $9.5M | $2.5M | +26% |
| Operating cash sources | $49.2M | $54.0M | −$4.8M | -9% |
| Depreciation & amortization | $578K | $536K | $42K | +8% |
| Share-based compensation | $10.1M | $10.5M | −$390K | -4% |
| Cash used in operations | $38.6M | $43.0M | −$4.4M | -10% |
| Net loss absorbed | $41.9M | $62.8M | −$20.9M | -33% |
| Working capital & other | $7.3M | −$8.9M | $16.2M | — |
Questions
How much did Nuvation Bio's revenue grow quarter over quarter in Q3 2026?
Nuvation Bio's revenue rose $13.3M (+42%) from $31.7M in Q2 2026 to $45.0M in Q3 2026.
What drove Nuvation Bio's revenue change in Q3 2026?
License +$9.0M (+106%); Product Revenue +$4.3M (+19%).